ADOCIA Announces its Financial Calendar for 2025

LYON, France--(BUSINESS WIRE)--Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2025.

February 25, 2025	Publication of revenue for Q4 2024
April 17, 2025	Publication of 2024 financial statements
May 14, 2025	Publication of revenue for Q1 2025
June 11, 2025	Annual shareholders’ meeting
July 23, 2025	Publication of revenue for Q2 2025
September 25, 2025	Publication of mid-year financial statements as of June 30, 2025
October 15, 2025	Publication of revenue for Q3 2025

In addition to regular meetings with the financial community, investors can also find updated information on the company’s website (www.adocia.com).

All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company’s website, in the Investors’ section “Regulated Information”.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone^® technology for the development of new generation insulins and products combining different hormones; 2) AdOral^®, an oral peptide delivery technology; 3) AdoShell^®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel^®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext^™ Paris (Euronext: ADOC; ISIN: FR0011184241).